Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Sales | 317,448 | 303,745 | 300,091 | 279,896 | 300,131 |
| Cost of Goods | 56,305 | 50,006 | 64,147 | 50,738 | 51,617 |
| Gross Profit | 261,143 | 253,739 | 235,944 | 229,158 | 248,514 |
| Operating Expenses | 300,260 | 273,953 | 325,712 | 289,981 | 821,937 |
| Operating Income | -38,812 | -20,208 | -89,621 | -60,085 | -572,806 |
| Interest Expense | 10,040 | 10,119 | 9,732 | 9,980 | 9,944 |
| Other Income | 3,306 | 6,021 | 7,187 | 3,252 | -195 |
| Pre-tax Income | -45,546 | -24,306 | -92,166 | -66,813 | -582,945 |
| Income Tax | -8,713 | -8,016 | -1,446 | -29,388 | -163,931 |
| Net Income Continuous | -36,833 | -16,290 | -90,720 | -37,425 | -419,014 |
| Net Income | $-36,833 | $-16,290 | $-90,720 | $-37,425 | $-419,014 |
| EPS Basic Total Ops | -0.21 | -0.09 | -0.49 | -0.22 | -2.58 |
| EPS Basic Continuous Ops | -0.21 | -0.09 | -0.48 | -0.22 | -2.58 |
| EPS Diluted Total Ops | -0.21 | -0.09 | -0.50 | -0.22 | -2.58 |
| EPS Diluted Continuous Ops | -0.21 | -0.09 | -0.48 | -0.22 | -2.58 |
| EBITDA(a) | $-19,060 | $-136 | $-68,895 | $-30,518 | $-543,922 |